NO934502D0 - Nye sulfonamider - Google Patents

Nye sulfonamider

Info

Publication number
NO934502D0
NO934502D0 NO934502A NO934502A NO934502D0 NO 934502 D0 NO934502 D0 NO 934502D0 NO 934502 A NO934502 A NO 934502A NO 934502 A NO934502 A NO 934502A NO 934502 D0 NO934502 D0 NO 934502D0
Authority
NO
Norway
Prior art keywords
new sulfonamides
sulfonamides
new
disorders
inhibitors
Prior art date
Application number
NO934502A
Other languages
English (en)
Other versions
NO306344B1 (no
NO934502L (no
Inventor
Volker Breu
Kasper Burri
Jean-Maria Cassal
Martine Clozel
Georges Hirth
Bernd-Michael Loeffler
Marcel Mueller
Werner Neidhart
Henri Ramuz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO934502D0 publication Critical patent/NO934502D0/no
Publication of NO934502L publication Critical patent/NO934502L/no
Publication of NO306344B1 publication Critical patent/NO306344B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
NO934502A 1992-12-10 1993-12-09 Nye sulfonamider, anvendelse derav og farmasöytiske preparater inneholdende dem NO306344B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH377792 1992-12-10
CH379992 1992-12-11
CH311493 1993-10-14

Publications (3)

Publication Number Publication Date
NO934502D0 true NO934502D0 (no) 1993-12-09
NO934502L NO934502L (no) 1994-06-13
NO306344B1 NO306344B1 (no) 1999-10-25

Family

ID=27174140

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934502A NO306344B1 (no) 1992-12-10 1993-12-09 Nye sulfonamider, anvendelse derav og farmasöytiske preparater inneholdende dem

Country Status (19)

Country Link
US (1) US5420129A (no)
EP (1) EP0601386B1 (no)
JP (1) JPH0826006B2 (no)
KR (1) KR100300503B1 (no)
CN (1) CN1049430C (no)
AT (1) ATE232204T1 (no)
AU (1) AU669019B2 (no)
CA (1) CA2110944A1 (no)
CZ (1) CZ288030B6 (no)
DE (1) DE59310329D1 (no)
DK (1) DK0601386T3 (no)
ES (1) ES2190430T3 (no)
FI (1) FI112217B (no)
HU (1) HUT65689A (no)
IL (1) IL107884A (no)
NO (1) NO306344B1 (no)
NZ (1) NZ250347A (no)
PH (1) PH30118A (no)
TW (1) TW287160B (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
TW313568B (no) * 1994-12-20 1997-08-21 Hoffmann La Roche
DE69528198T2 (de) * 1994-12-20 2003-07-31 Hoffmann La Roche Aryl-und hetaryl-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
ES2156305T3 (es) * 1995-12-20 2001-06-16 Yamanouchi Pharma Co Ltd Derivados de ariletenosulfonamida y composiciones de farmacos que los contienen.
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
WO1997029747A1 (en) 1996-02-20 1997-08-21 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AR048563A1 (es) * 1996-09-16 2006-05-10 Univ Dalhousie Metodos para el tratamiento de la enfermedad renal poliquistica en un mamifero, la insuficiencia renal, el desarrollo glomerular y de los rinones y proteger de la toxicidad por hormonas esteroides y uso de la igf- i para la fabricacion de una composicion farmaceutica.
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
CA2496680A1 (en) 1997-04-28 1998-11-05 Encysive Pharmaceuticals Inc. Sulfonamide compounds and salts for treatment of endothelin-mediated disorders
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
HUP0201320A2 (en) 1999-03-19 2002-08-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
CA2397258C (en) * 2000-01-25 2007-07-03 F. Hoffmann-La Roche Ag Preparation of sulfonamides
AU2001263850A1 (en) * 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
MY140724A (en) * 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
ES2258668T3 (es) * 2001-10-26 2006-09-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hidroxipirimidina carboxamidas n-sustituidas inhibidoras de hiv integrasa.
US7232819B2 (en) 2001-10-26 2007-06-19 Istituto Di Ricerche Di Biologia P. Angeletti S.P.A. Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003248549B2 (en) * 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
DE102004027119A1 (de) 2003-06-06 2004-12-30 Schott Ag UV-Strahlung absorbierendes Glas mit geringer Absorption im sichtbaren Bereich, ein Verfahren zu seiner Herstellung sowie dessen Verwendung
CN1849318B (zh) * 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
PL1763517T3 (pl) 2004-06-28 2011-10-31 Hoffmann La Roche Pochodne pirymidyny jako inhibitory 11BETA-HSD1
KR100847203B1 (ko) * 2004-06-28 2008-07-17 에프. 호프만-라 로슈 아게 피리미딘 유도체
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
CA2604551A1 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
EP1996162A2 (en) * 2006-03-13 2008-12-03 Encysive Pharmaceuticals, Inc Methods and compositions for treatment of diastolic heart failure
WO2007106468A2 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Formulations of sitaxsentan sodium
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
EP2240470A4 (en) * 2008-01-10 2012-05-23 Msn Lab Ltd IMPROVED AND NEW PROCESS FOR THE PREPARATION OF BOSENTAN
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
KR101467858B1 (ko) * 2009-12-28 2014-12-02 재단법인 생물기술개발중심 ｍＴＯＲ 및 ＰＩ３Ｋ 억제제로서의 신규 피리미딘 화합물
US10195198B2 (en) * 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
JP2023525349A (ja) 2020-05-12 2023-06-15 バイエル、アクチエンゲゼルシャフト 殺真菌性化合物としてのトリアジンおよびピリミジン（チオ）アミド化合物
JP2023528891A (ja) 2020-06-04 2023-07-06 バイエル、アクチエンゲゼルシャフト 新規殺真菌剤としてのヘテロシクリルピリミジンおよびトリアジン
WO2023078463A1 (zh) * 2021-11-08 2023-05-11 正大天晴药业集团股份有限公司 氮杂联苯类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270116B (no) * 1991-04-25 1996-02-11 Hoffmann La Roche

Also Published As

Publication number Publication date
IL107884A (en) 1998-03-10
JPH0826006B2 (ja) 1996-03-13
NO306344B1 (no) 1999-10-25
EP0601386B1 (de) 2003-02-05
NO934502L (no) 1994-06-13
FI112217B (fi) 2003-11-14
CZ288030B6 (cs) 2001-04-11
IL107884A0 (en) 1994-04-12
KR100300503B1 (ko) 2001-11-22
ATE232204T1 (de) 2003-02-15
FI935555A0 (fi) 1993-12-10
TW287160B (no) 1996-10-01
JPH06211810A (ja) 1994-08-02
KR940014347A (ko) 1994-07-18
DK0601386T3 (da) 2003-05-26
AU669019B2 (en) 1996-05-23
US5420129A (en) 1995-05-30
DE59310329D1 (de) 2003-03-13
CA2110944A1 (en) 1994-06-11
CZ268493A3 (en) 1994-06-15
HUT65689A (en) 1994-07-28
EP0601386A1 (de) 1994-06-15
NZ250347A (en) 1995-12-21
FI935555A (fi) 1994-06-11
CN1095375A (zh) 1994-11-23
HU9303458D0 (en) 1994-04-28
AU5218993A (en) 1994-06-23
PH30118A (en) 1996-12-27
CN1049430C (zh) 2000-02-16
ES2190430T3 (es) 2003-08-01

Similar Documents

Publication Publication Date Title
NO934502D0 (no) Nye sulfonamider
NO942428D0 (no) Nye sulfonamidopyrimidiner
NO892894D0 (no) Nye kondenserte heterocykliske forbindelser.
DE59310146D1 (de) Sulfonamidocarbonylpyridin-2-carbonsäureamide und ihre Verwendung als Arzneimittel
NO931695D0 (no) Nye 4-arylpiperaciner og 4-arylpiperidiner
NO944406D0 (no) Nye 7 se inhibitorer
MX9201760A (es) Quinoxalinas, procedimiento para su preparacion y su empleo.
DE3774858D1 (de) Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
DE59105960D1 (de) Oxazolidinone mit ZNS-dämpfender Wirkung.
DE69208759D1 (de) Salze von N-Nitrosophenylhydroxylamin
DK435089A (da) Anvendelse af zofenopril til behandling af rheumatoid arthritis
ATE119394T1 (de) Verwendung von myricetin-3-0-beta-d-glucuronid als arzneimittel.
IT1262952B (it) Tetraalchilpiperidine, loro preparazione e loro impiego come stabilizzanti alla luce. (caso 153-5502)